Immunogenicity
Eighty-three subjects with SHR-1222 were included in the immunogenicity analyses, among whom six (7.2%) tested positive for anti-SHR-1222 antibodies after administration (100 mg QM, n=1; 300 mg QM, n=1; 400 mg Q2M, n=1; 600 mg Q2M, n=3). However, the development of anti-SHR-1222 antibodies had no discernible effect on the main dose-standardized PK parameters (such as C